{"entity":{"type":"insider","cik":"0001780408","url":"/insider/0001780408","json_url":"/insider/0001780408.json","name":"KKR Genetic Disorder L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":6,"n_filings":6,"first":"2019-07-03","last":"2025-05-14","span_basis":"filed_date"},"name_variants":[{"name":"KKR Genetic Disorder L.P.","source":"filing","n_filings":6,"first_seen":"2019-07-03","last_seen":"2025-05-14"}],"transactions":[{"id":4297371,"accession":"0001140361-25-019003","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-25-019003","line_url":"/filing/0001140361-25-019003#line-1","is_derivative":false,"issuer_cik":"0001081714","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001081714","owner_cik":null,"owner_name":"KKR & Co. Inc.; KKR Genetic Disorder GP LLC; KKR Genetic Disorder L.P.; KKR Group Co. Inc.; KKR Group Holdings Corp.; KKR Group Partnership L.P.; KKR Management LLP; KRAVIS HENRY R; ROBERTS GEORGE R","owner_display_name":"KKR & Co. Inc.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6000000.0,"shares_display":"6,000,000","price_per_share":34.2,"price_display":"34.20","price_state":"stated","total_value":205200000.0,"total_display":"205,200,000.00","total_whole":"205,200,000","shares_owned_after":13260971.0,"shares_owned_after_display":"13,260,971","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-12","filed_date":"2025-05-14","scope":"insider"},{"id":4939698,"accession":"0001140361-25-007699","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-25-007699","line_url":"/filing/0001140361-25-007699#line-1","is_derivative":false,"issuer_cik":"0001081714","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001081714","owner_cik":null,"owner_name":"KKR & Co. Inc.; KKR Genetic Disorder GP LLC; KKR Genetic Disorder L.P.; KKR Group Co. Inc.; KKR Group Holdings Corp.; KKR Group Partnership L.P.; KKR Management LLP; KRAVIS HENRY R; ROBERTS GEORGE R","owner_display_name":"KKR & Co. Inc.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6000000.0,"shares_display":"6,000,000","price_per_share":32.96,"price_display":"32.96","price_state":"stated","total_value":197760000.0,"total_display":"197,760,000.00","total_whole":"197,760,000","shares_owned_after":19260971.0,"shares_owned_after_display":"19,260,971","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-03-05","filed_date":"2025-03-07","scope":"insider"},{"id":2841957,"accession":"0001140361-24-041329","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-24-041329","line_url":"/filing/0001140361-24-041329#line-1","is_derivative":false,"issuer_cik":"0001081714","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001081714","owner_cik":null,"owner_name":"KKR & Co. Inc.; KKR Genetic Disorder GP LLC; KKR Genetic Disorder L.P.; KKR Group Co. Inc.; KKR Group Holdings Corp.; KKR Group Partnership L.P.; KKR Management LLP; KRAVIS HENRY R; ROBERTS GEORGE R","owner_display_name":"KKR & Co. Inc.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5800000.0,"shares_display":"5,800,000","price_per_share":25.75,"price_display":"25.75","price_state":"stated","total_value":149350000.0,"total_display":"149,350,000.00","total_whole":"149,350,000","shares_owned_after":25260971.0,"shares_owned_after_display":"25,260,971","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-13","filed_date":"2024-09-17","scope":"insider"},{"id":5289717,"accession":"0001140361-21-005267","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-21-005267","line_url":"/filing/0001140361-21-005267#line-1","is_derivative":false,"issuer_cik":"0001081714","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001081714","owner_cik":null,"owner_name":"KKR & Co. Inc.; KKR Genetic Disorder GP LLC; KKR Genetic Disorder L.P.; KKR Group Holdings Corp.; KKR Group Partnership L.P.; KKR Management LLP; KRAVIS HENRY R; ROBERTS GEORGE R","owner_display_name":"KKR & Co. Inc.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3450000.0,"shares_display":"3,450,000","price_per_share":60.4688,"price_display":"60.47","price_state":"stated","total_value":208617360.0,"total_display":"208,617,360.00","total_whole":"208,617,360","shares_owned_after":31060971.0,"shares_owned_after_display":"31,060,971","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-17","filed_date":"2021-02-17","scope":"insider"},{"id":2264426,"accession":"0001140361-20-012852","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-20-012852","line_url":"/filing/0001140361-20-012852#line-1","is_derivative":false,"issuer_cik":"0001081714","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001081714","owner_cik":null,"owner_name":"KKR & Co. Inc.; KKR Genetic Disorder GP LLC; KKR Genetic Disorder L.P.; KKR Group Holdings Corp.; KKR Group Partnership L.P.; KKR Management LLP; KRAVIS HENRY R; ROBERTS GEORGE R","owner_display_name":"KKR & Co. Inc.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2389690.0,"shares_display":"2,389,690","price_per_share":33.39,"price_display":"33.39","price_state":"stated","total_value":79791749.1,"total_display":"79,791,749.10","total_whole":"79,791,749","shares_owned_after":34510971.0,"shares_owned_after_display":"34,510,971","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-28","filed_date":"2020-06-01","scope":"insider"},{"id":8345470,"accession":"0000899243-19-019173","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-019173","line_url":"/filing/0000899243-19-019173#line-2","is_derivative":false,"issuer_cik":"0001081714","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001081714","owner_cik":null,"owner_name":"KKR Management LLC; KKR Management Holdings L.P.; KRAVIS HENRY R; KKR Genetic Disorder GP LLC; KKR & Co. Inc.; ROBERTS GEORGE R; KKR Genetic Disorder L.P.; KKR Management Holdings Corp; KKR Group Holdings Corp.","owner_display_name":"KKR Management LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2647100.0,"shares_display":"2,647,100","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":45000700.0,"total_display":"45,000,700.00","total_whole":"45,000,700","shares_owned_after":36900661.0,"shares_owned_after_display":"36,900,661","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-07-01","filed_date":"2019-07-03","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001743881","name":"BridgeBio Pharma, Inc.","url":"/issuer/0001743881","role":"Ten percent owner","n_filings":6,"first_seen":"2019-07-03","last_seen":"2025-05-14"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001780408","retrieved_at":"2026-08-22T08:58:40+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}